Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Paul Grint, Jennifer Doudna, Emmanuelle Charpentier


Regulus Therapeutics has appointed Paul Grint as its chief medical officer.

Grint joins the company from Cerexa, a subsidiary of Forest Laboratories, where he served as president and was responsible for the company's anti-infective product pipeline. Before that, he was senior vice president of research at Forest Research Institute.

Johnson & Johnson has announced that University of California, Berkeley's Jennifer Doudna and Hannover Medical School's Emmanuelle Charpentier have been named the winners of this year's Dr. Paul Janssen Award for Biomedical Research.

Doudna and Charpentier received the award for their groundbreaking research into CRISPR-Cas9, a bacterial immunity mechanism in which a short strand of RNA guides a nuclease to a specific area of DNA where it triggers double-strand breaks. The technology has since been refined and adopted by researchers for gene-editing applications.